Oncology

Back to articles

Practice-changing data for nonmetastatic, castrate-resistant prostate cancer

KEY POINT

Two trials published in the New England Journal of Medicine showed that use of the next-generation androgen-receptor blockers apalutamide (Erleada—Janssen) or enzalutamide (Xtandi—Astellas) in men with nonmetastatic, castration-resistant prostate cancer (nmCRPC) significantly prolonged metastasis-free survival (MFS) and improved several other secondary endpoints, compared with placebo.

 

SOURCES

Smith MR, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–18.

Hussain M, et al. Enzalutamide in men with non-metastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(15):2465–74.

Smith MR. Progress in non-metastatic prostate cancer. N Engl J Med. 2018;378(26):2531–2.